Table 2. Antimicrobial susceptibility of C. jejuni.
| Antimicrobiala | MIC (µg/ml)b | |||||||
| NCTC 11168 | 81-176 | |||||||
| Ia | IIa | IIIa | IVa | Ib | IIb | IIIb | IVb | |
| (wild-type, 168gmhA) | (168cj1136, 168cj1138) | (168waaF, 168cj1135) | (168hldE, 168hldD, 168waaC) | (wild-type, 817gmhA) | (817cjj1152, 817cjj1165) | (817waaF) | (817hldE, 817hldD, 817waaC) | |
| Ox gall | 25,000 | 25,000 | 25,000 | 6,250 | 12,500 | 12,500 | 6,250 | 6,250 |
| Ox bile extract | 12,500 | 12,500 | 12,500 | 3,130 | 6,250 | 6,250 | 3,130 | 3,130 |
| Cholic acid | 6,250 | 3,130 | 3,130 | 1,560 | 3,130 | 3,130 | 780 | 780 |
| Deoxycholic acid | >10,000 | 10,000 | 5,000 | 313 | >10,000 | 10,000 | 625 | 313 |
| Taurocholic acid | >100,000 | 100,000 | 100,000 | 12,500 | >100,000 | 100,000 | 12,500 | 12,500 |
| SDS | 100 | 100 | 100 | 50 | 50 | 50 | 25 | 25 |
| Ampicillin | >50 | >50 | >50 | >50 | 3.13 | 3.13 | 3.13 | 3.13 |
| Cefsulodin | 25 | 25 | 25 | 25 | 12.5 | 12.5 | 12.5 | 12.5 |
| Gentamicin | 0.313 | 0.313 | 0.313 | 0.313 | 0.313 | 0.313 | 0.313 | 0.313 |
| Tetracycline | <0.2 | <0.2 | <0.2 | <0.2 | 6.25 | 6.25 | 6.25 | 6.25 |
| Erythromycin | 0.5 | 0.125 | 0.125 | 0.0625 | 0.125 | 0.125 | 0.0625 | 0.0313 |
| Trimethoprim | 500 | 500 | 500 | 500 | 250 | 250 | 250 | 250 |
| Nalidixic acid | 10 | 10 | 10 | 10 | 2.5 | 2.5 | 2.5 | 2.5 |
| Enrofloxacin | 0.0625 | 0.0625 | 0.0625 | 0.0625 | 0.0313 | 0.0313 | 0.0313 | 0.0313 |
| Rifampin | 200 | 200 | 200 | 100 | 100 | 100 | 50 | 50 |
| Polymyxin B | 5 | 2.5 | 2.5 | 2.5 | 2.5 | 1.25 | 1.25 | 1.25 |
a
Bold-faced types indicate that the differences in MICs observed between NCTC 11168 or 81-176 wild-type strain and any mutant.
b
The NCTC 11168 or 81-176 wild-type strain and mutants were divided into four groups (Ia–IVa or Ib–IVb) on the basis of MICs. The strains belonging to the same group showed identical MIC values for all of the antimicrobials tested.